Aktienanalyse zu Prokidney Corp (PROK)PROKProkidney Corp

Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

ProKidney Corp is not a good buy right now. The current price is $1.33, and the stock has seen a significant 59.57% decline over the past year. Additionally, the RSI is at a low 20.445, indicating oversold conditions, but this does not guarantee a price rebound. The company continues to report substantial losses, with a net income of -$28.42 million in Q2 2026, raising concerns about its financial stability. The main risk is the ongoing negative cash flow and operational losses, which could further impact investor confidence.